S1P1 Receptor Modulators for Selective Lymphocyte Sequestration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by sphingosine-1-phosphate receptor activation lack effective modulators that can selectively target specific receptor subtypes to achieve desired therapeutic effects.
Innovation Solution
Development of compounds, such as those represented by Formula (I), which act as modulators of the S1P1 receptor subtype, including both orthosteric and allosteric agonists, to selectively activate or modulate the S1P1 receptor for signal transduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current treatments for sphingosine-1-phosphate receptor mediated conditions are used, then general therapeutic effects are achieved, but selective targeting of specific receptor subtypes is lacking
Solution Approach 1:
The patent segments the sphingosine-1-phosphate receptor system into five distinct subtypes (S1P1, S1P2, S1P3, S1P4, and S1P5), each with different tissue expression patterns and cell specificities. By designing modulators that can selectively target specific subtypes, the patent achieves precise receptor subtype selectivity while maintaining broad therapeutic applicability across different conditions mediated by these receptors.
Solution Approach 2:
The patent applies local quality by creating modulators with specific binding characteristics for different receptor subtypes. Each modulator is designed to interact preferentially with particular receptor subtypes based on their unique structural and functional properties, enabling selective activation or inhibition of specific S1P receptor subtypes in different tissue contexts.
2Productivity
If S1P1 receptor agonism is used to sequester lymphocytes in lymph nodes, then rapid and reversible lymphopenia is achieved, but the mechanism involves complex receptor ligation on both endothelial cells and lymphocytes
Solution Approach 1:
The patent utilizes the S1P1 receptor as an intermediary mechanism to achieve lymphopenia. The modulators bind to S1P1 receptors on both lymphatic endothelial cells and lymphocytes, triggering a coordinated signaling response that efficiently sequesters lymphocytes in lymph nodes. This intermediary receptor system simplifies the overall process by providing a defined molecular target that mediates the complex interaction between endothelial cells and lymphocytes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide targeted integration with the S1P1 receptor, activating it for signal transduction and offering therapeutic potential for conditions where S1P1 receptor activation is medically indicated.
Implementation Method 1
Like all GPCRs, ligation of the receptor propagates second messenger signals via activation of G-proteins (alpha, beta and gamma)
Data Source
AI summary
Compounds are provided having the structure of Formula (I): (Formula (I)) or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein R is as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate receptor, and have utility for treatment of a malcondition for which activation of this receptor is medically indicated.